The mission of the Van Rijn lab is to uncover new strategies to treat psychiatric and neurological disorders. We specifically investigate the heavily co-morbid triad of drug use disorders, chronic pain disorders and mood disorders. Our primary target, the delta opioid receptor, is involved in the neuropharmacology of all three disorders and thus offers an exciting novel approach to treat these disorders. The Van Rijn lab covers all aspects of preclinical drug development including drug synthesis, drug screening, pharmacological characterization both in vitro and in vivo. We also perform mechanistic studies to improve our understanding of the etiology of these disorders.
News - 2021April 30th, 2021 - Big congratulations to Arryn Blaine for winning the ASPET Dolores C. Shockley poster award for her poster titled "Role of beta-arrestin Isoforms in Delta Opioid Receptor Agonist-Induced Seizures"
April 28th, 2021 - Dr. van Rijn was selected by the International Narcotics Research Conference as their 2021 Young Investigator Award winner April 23rd, 2021 - The Van Rijn lab contributed to a preprint by the Majumdar lab titled "A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects". April 23rd, 2021 - A multi-site team consisting of the Van Rijn and Chopra Labs at Purdue and Dr. Timothy Richardson (IUSM), Daniel Robertson (IBRI) was one of the five teams to receive a 2020 NCATS ASPIRE Reduction-to-Practice Challenge Prize for a project titled "Accelerating Molecular Innovation in Pain through an AI-Driven, Human-Guided, and Automated Open Drug Discovery Platform" April 23rd, 2021 - The Leung Lab's paper Drug Screening with Zebrafish Visual Behavior Identifies Carvedilol as a Potential Treatment for an Autosomal Dominant form of Retinitis Pigmentosa that we collaborated on has been accepted in Scientific Reports. April 1st, 2021 - Dr. van Rijn has joined the editorial board of Advances in Drug and Alcohol Research - a new official journal of the International Drug Abuse Research Society and the International Narcotics Research Conference. March 23rd, 2021 - Dr. van Rijn and collaborators Drs Lill and Cushman were awarded a US patent 10,954,224 on delta opioid agonists. March 23rd, 2021 - Dr. van Rijn presented a virtual seminar on "Identification of Natural and Synthetic Opioids to Treat Neurological Disorders" to chemistry students at Olivet Nazerene University. March 1st, 2021 - Congratulations to Alex French for receiving an incentive award from the Purdue Animal Behavior Core to study the effects of kappa opioid drugs on ataxia. January 11-13th, 2021 - Arryn Blaine and Alex French presented virtual posters at the Society for Neuroscience Global Connectome meeting. Arryn presented her poster titled "beta-arrestin recruitment is correlated with Delta Opioid Receptor Agonist-Induced Seizure Severity", Alex's poster was titled "Relating alcohol consumption behavior to ligand bias at the kappa opioid receptor" January 11th, 2021 - Congratulations to Arryn Blaine for winning best poster during the PULSe Graduate recruitment event. Donate to science.
If you appreciate the research carried out in the Van Rijn lab and support our goals feel free to donate to the advancement of science. Donations will be used to help support (undergraduate) students and carry out experiments exploring exciting new preliminary projects, currently not funded through other mechanisms. Donations can be made by specifically mentioning the Van Rijn lab at the following Purdue University website: Purdue Research Foundation: Giving to Purdue Instructions on types of donations Science trumps politics. Register.Vote. Help others to register and vote. Apathy leads to stupidity.
|
RECENT PUBLICATIONSApril 23rd, 2021 - The Van Rijn lab contributed to a preprint by the Majumdar lab titled "A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects".
April 23rd, 2021 - The Leung Lab's paper Drug Screening with Zebrafish Visual Behavior Identifies Carvedilol as a Potential Treatment for an Autosomal Dominant form of Retinitis Pigmentosa that we collaborated on has been accepted in Scientific Reports. December 6th, 2020 - Mee Jung Ko's thesis project manuscript "beta-arrestin depedendent ERK signaling positively correlates with reduced anxiety-like and conditioned fear-related behavior in mice" has been accepted for publication in Science Signaling. December 2nd, 2020 - The Riley/Van Rijn manuscript "Isolation and Pharmacological Characterization of Six Opioidergic pricalima Nitada Alkaloids." has been accepted for publication in the Journal of Natural Products. November 25th, 2020 - A paper by the Watts lab that we collaborated on, titled "The CUL3/neddylation inhibitor MLN4924 reduces ethanol-induced locomotor sensitization and inflammatory pain allodynia in mice" has been accepted for publication in Behavioural Brain Research October 11th, 2020 - A paper by Dr. Pradhan at UIC "A non-convulsant DOR agonist, KNT-127, reduces cortical spreading depression and nitroglycerin induced allodynia", that Dr. van Rijn collaborated on was accepted by the journal Headache Disclaimer of opinion
The information, statements and opinions presented on the the Van Rijn lab website are solely expressed by Dr. van Rijn and do not necessarily represent views held by Purdue University. |
|
Proudly powered by Weebly